Tenders Are Invited For Pharmaceutical Products – Conclusion Of Non-Exclusive Discount Agreements In Accorda ...
Tender Notice
TenderID
78961979
Tender Brief
Tenders Are Invited For Pharmaceutical Products – Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V For Pharmaceuticals (Open House Procedure)
Pharmaceutical Products – Conclusion Of Non-Exclusive Discount Agreements In Accordance With Section 130A Paragraph 8 Sgb V For Pharmaceuticals (Open House Procedure). The Procurement Requirement Includes All Medicinal Products With The Active Ingredients Named In Appendix 3 To The Conditions Of Participation (So-Called List Of Active Ingredients And Deadlines). The Procurement Requirements Were Not Divided Into Lots. This Is An Open House Procedure. To The Extent That Wording Is Used In This Announcement That Indicates The Division Of Procurement Requirements Into One Or More Lots, This Is Solely Due To The Specifications Of This Announcement Form. In This Context, Reference Is Made To The Non-Applicability Of Procurement Regulations Described At The Beginning Of Section 2.1. The Aok Starts The Open House Process With The Following Active Ingredients (So-Called Starting Active Ingredients): 1. Aripiprazole* (Serial No. 1 Of Appendix 3 To The Conditions Of Participation); 2. Glatiramer Acetate (Section No. 2 Of Appendix 3 To The Conditions Of Participation); 3. Peginterferon Beta-1A (Section No. 3 Of Appendix 3 To The Conditions Of Participation); 4. Somatropin (Section No. 4 Of Appendix 3 To The Conditions Of Participation); 5. Ustekinumab (Section No. 5 Of Appendix 3 To The Conditions Of Participation). *For Medicines With The Active Ingredient Aripiprazole, Only Medicines With This Active Ingredient In The Sustained-Release Dosage Forms With The Atc Code N05ax12 Are Required For Procurement. The Aok Reserves The Right To Expand The Procurement Requirements Of This Open House Procedure As The Procedure Progresses, I.E. H. Appendix 3 To The Conditions Of Participation Should Be Supplemented With Additional Active Ingredients. This Means That Discount Agreements For Medicines With These Other Active Ingredients Would Also Be Subject To The Present Open House Procedure. Of Course, This Would Not Expand The Content Of Contracts Already Concluded For Other Active Ingredients, But Rather A New Contract Would Have To Be Concluded For Each Active Ingredient (See Also Sections A.I.1, A.I.4 And A.Iii.4 Of The Conditions Of Participation). If The Aok Decides To Expand The Procurement Requirements, It Will Announce This Fact In A Further Contract Announcement (So-Called Follow-Up Announcement), Which Refers To This Contract Announcement Here (So-Called Initial Announcement), In The Supplement To The Official Journal Of The European Union. Further Information On A Possible Expansion Of Procurement Requirements Is Contained In The Conditions Of Participation (Section A.I.4). Contracts For Medicines With The Starting Active Ingredients Will Not Be Concluded Until July 1, 2024 At The Earliest. All Discount Agreements Concluded As Part Of This Open House Procedure End On June 30, 2026. For The Earliest Possible Start Of The Contract On July 1, 2024, Interested Companies Must Submit A Complete Offer In Accordance With The Participation Documents Exclusively In Electronic Form Via The Communication Area Of The Procurement Platform By May 17, 2024 At The Latest. Discount Contracts For Medicines With The Starting Active Ingredients Will Not Be Concluded Until May 28, 2024 At The Earliest (Waiting And Standstill Period). The Graduation
Dear Sir,
Warm Greetings from TenderDetail.com !!
We have received Tender Document request for the TDR No : 78961979
Tender Notice along with it's Attachments ( Tender Document / Scan Image of News Paper)
sent to your Email Address :.
Please check your email for Tender Document.